Skip to main content
MyCapitol LogoMyCapitol

S 5571 · 119th Congress

Biosimilars Access and Affordability Act

This bill changes when cheaper generic versions of biologic drugs (called biosimilars) become eligible for Medicare price negotiations. Currently, biosimilars can be negotiated immediately once they're approved by the FDA. This bill delays that eligibility by up to 2 years if a biosimilar is expected to enter the ma…

Sponsor
Blackburn, Marsha (R-Tennessee)
Introduced
2026-09-28
Policy area
Health

Digging through Congress... 🔍